Ultragenyx Pharmaceutical Inc. (RARE)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
Show:
Annual
Cash flow
All numbers in thousandsBreakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-606,639
-606,639
-707,421
-454,025
-186,566
Depreciation & amortisation
26,006
26,006
18,220
13,239
12,261
Stock-based compensation
135,227
135,227
130,377
104,952
85,735
Change in working capital
-15,101
-15,101
60,235
-63,236
104,663
Accounts receivable
-22,778
-22,778
-12,068
-5,432
9,840
Inventory
-6,930
-6,930
-9,701
-3,117
-1,346
Accounts payable
-
-
87,442
32,313
-
Other working capital
-521,573
-521,573
-526,588
-411,788
-176,125
Other non-cash items
-1,060
-1,060
96,126
11,706
21,242
Net cash provided by operating activities
-474,806
-474,806
-380,465
-338,695
-132,220
Cash flows from investing activities
Investments in property, plant and equipment
-46,767
-46,767
-146,123
-73,093
-43,905
Acquisitions, net
0
0
-75,025
0
-
Purchases of investments
-526,382
-526,382
-614,735
-1,012,187
-850,299
Sales/maturities of investments
746,197
746,197
545,075
890,850
720,638
Other investing activities
-5,048
-5,048
-844
-942
-5,555
Net cash used for investing activities
168,000
168,000
-291,652
-195,372
-179,121
Cash flows from financing activities
Debt repayment
-33
-
-
-
-
Common stock issued
379,755
379,755
0
78,943
511,215
Other financing activities
-28
-28
490,395
-492
-236
Net cash used provided by (used for) financing activities
388,142
388,142
501,208
118,552
600,272
Net change in cash
81,798
81,798
-171,984
-416,709
290,050
Cash at beginning of period
137,601
137,601
309,585
726,294
436,244
Cash at end of period
219,399
219,399
137,601
309,585
726,294
Free cash flow
Operating cash flow
-474,806
-474,806
-380,465
-338,695
-132,220
Capital expenditure
-46,767
-46,767
-146,123
-73,093
-43,905
Free cash flow
-521,573
-521,573
-526,588
-411,788
-176,125
© 2024 Yahoo. All rights reserved.